Sector News

BioMarin snaps up Prosensa for around $840m

November 24, 2014
Life sciences
BioMarin Pharmaceuticals is acquiring Dutch group Prosensa in a deal valued at up to around $840 million.
 
The group said it will offer to buy all of Prosensa’s outstanding ordinary stock for $17.75 per share, for a total upfront consideration of around $680 million, as well as two $80-million milestones contingent on the approval of drisapersen for Duchenne Muscular Dystrophy (DMD) in the US (no later than May 15, 2016) and Europe (before February 15, 2017).
 
The move buys BioMarin access to multiple orphan-drug candidates – such as drisapersen, which has a shot at becoming first approved treatment for the rare genetic disease, albeit for about just 13% of patients (who carry a particular mutation) – leveraging the firm’s proprietary RNA-modulating technology platform for the treatment of various genotypes of DMD and other genetic disorders.      
 
The transaction is expected to be accounted for as a business combination, BioMarin said, also noting that it plans to maintain operations at Prosensa’s headquarters, based in Leiden, The Netherlands and integrate personnel from that office. 
 
“BioMarin is dedicated to the rare disease community, and the acquisition of Prosensa fits strategically with our mission of delivering therapies that address serious unmet medical needs,” said its chief Jean-Jacques Bienaimé, while Prosensa’s head said the move while help his firm’s mission by “bringing innovative therapies to patients across the world as quickly and efficiently as possible”.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach